Skip to main content
. Author manuscript; available in PMC: 2008 Nov 5.
Published in final edited form as: J Pain. 2008 Jul 16;9(11):991–998. doi: 10.1016/j.jpain.2008.05.006

Figure 4.

Figure 4

A: I.t. administration of the CRF2 receptor antagonist, aSVG30, significantly attenuated the augmentation of bladder nociceptive responses induced by urocortin 2 (** indicates significant difference from aSVG30 + urocortin 2 and from aSVG30 + vehicle at p<0.01). B: In contrast, i.t. administration of the CRF1 receptor antagonist, antalarmin, had no effect on UBD-evoked VMRs. N=5-8/group.